- Home
- PMN vs ELEV Comparison
PMN vs ELEV Comparison
Compare PMN & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- ELEV
- Stock Information
- Founded
- PMN 2004
- ELEV 2019
- Country
- PMN Canada
- ELEV United States
- Employees
- PMN 8
- ELEV N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- PMN Health Care
- ELEV Health Care
- Exchange
- PMN Nasdaq
- ELEV Nasdaq
- Market Cap
- PMN 17.0M
- ELEV 18.1M
- IPO Year
- PMN N/A
- ELEV 2021
- Fundamental
- Price
- PMN $0.48
- ELEV $0.32
- Analyst Decision
- PMN Strong Buy
- ELEV Buy
- Analyst Count
- PMN 2
- ELEV 6
- Target Price
- PMN $4.50
- ELEV $2.94
- AVG Volume (30 Days)
- PMN 55.0K
- ELEV 750.8K
- Earning Date
- PMN 05-12-2025
- ELEV 08-05-2025
- Dividend Yield
- PMN N/A
- ELEV N/A
- EPS Growth
- PMN N/A
- ELEV N/A
- EPS
- PMN N/A
- ELEV N/A
- Revenue
- PMN N/A
- ELEV N/A
- Revenue This Year
- PMN N/A
- ELEV N/A
- Revenue Next Year
- PMN N/A
- ELEV N/A
- P/E Ratio
- PMN N/A
- ELEV N/A
- Revenue Growth
- PMN N/A
- ELEV N/A
- 52 Week Low
- PMN $0.47
- ELEV $0.22
- 52 Week High
- PMN $2.37
- ELEV $3.77
- Technical
- Relative Strength Index (RSI)
- PMN 40.42
- ELEV 49.38
- Support Level
- PMN $0.47
- ELEV $0.29
- Resistance Level
- PMN $0.56
- ELEV $0.32
- Average True Range (ATR)
- PMN 0.06
- ELEV 0.02
- MACD
- PMN 0.00
- ELEV 0.00
- Stochastic Oscillator
- PMN 5.71
- ELEV 59.01
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.